News and Announcements
Why Raising Money Costs Money
- Published December 20, 2022 1:37AM UTC
- Publisher Leila Oliveira
- Categories Capital Raising Tips
The inconvenient truth: Raising money costs money.
You need to allocate a budget to raise capital.
I’ll explain why:
To successfully launch a product you would create plans, grow the team, have a budget and clear strategies. Right?
So why when it comes to raising capital that will transform your business, you don’t have a clear plan with budget, timelines and strategies?
Think with me: You will need to attract investors, build the network, create certainty and interest, get their trust, and then close it.
(It’s not over yet)
After closing, you need to keep communicating with current investors PLUS reaching out to new investors. It’s an ongoing job ON TOP of your full-time job.
So, remember…
Raising capital will change your business and pay off in the end,
Just make sure you’re ready for it.
Looking for a platform to raise capital? Click here to discover how Wholesale Investor can help you.
Your capital engagement platform
With a 14-year track record, a network of 32,000+ investors, and a capital raising platform, Wholesale investor is a leading investment platform for start-ups, scale-ups, emerging growth companies, and small caps.
Capital Raising Tips
The Biofilm Breakthrough: How An Australian BioTech Firm Is Tapping Indonesia’s $45,000-a-Kitchen Bottleneck
Australian sustainability and deep-tech firm Altair International Pty Ltd is commercialising plant-based clinical hygiene technology, targeting a prime operational bottleneck in Indonesia’s massive national free meals program. Every few years, an Australian deep-tech company emerges combining proprietary science with a transformational anchor contract, the kind of business that quietly creates an entirely new market category […]
THE TAX CHANGED. NOW THE PRODUCT IS CHANGING TO MATCH.
Changes to the 50% capital gains tax discount are shifting Australian private capital away from growth and into high-yielding wrappers. Fund managers are actively redesigning products across private credit and property to capture the incoming capital rotation
The Algorithm Re-Dosing Cancer Treatment: Inside the University of Melbourne Spin-Out Rewriting a 60-Year-Old Formula
Oncology specialists are still calculating toxic chemotherapy doses using a formula from the era of the Ford Model T, leading to a system where seven out of eight patients are routinely overdosed. University of Melbourne spin-out PredicTx is dismantling this legacy approach, utilizing advanced AI to analyze existing patient CT scans, deliver precision medicine to the bedside, and return a massive 100x financial rerate to hospital networks.
Backed By Leading Investment Groups and Family Offices
